Publication date: Sep 01, 2024

There is an overlap between symptoms of perimenopause/menopause and post-COVID syndrome and there is a concern that some female patients referred to post-COVID syndrome clinics may have undiagnosed perimenopause/menopause. However, the prevalence of such symptoms in this population is unknown. Cross-sectional analysis of 122 women’s health questionnaires as part of a service improvement project in three National Health Service post-COVID syndrome clinics in England. The primary outcomes were prevalence of menopause symptoms and association between the total menopause symptom questionnaire (MSQ) score and the key predictors. Age group 40-54 years showed the highest prevalence of most individual symptoms and the highest mean total MSQ score (36. 4; confidence interval [CI] 32. 3-40. 6), correlating clinically with the onset of perimenopause/menopause. Regression modeling shows a significant positive parabolic relationship between age and total MSQ score. Age group 40-54 years is associated with a 6. 60-point higher (CI 1. 31-11. 9) total MSQ score than the age group 55-79 years; an increase of one index of multiple deprivation quintile is associated with a 2. 85-point lower (CI -1. 24 to -4. 45) total MSQ score; presence of a gynecologic diagnosis is associated with a 6. 31-point higher (CI 1. 32-11. 3) total MSQ score. A total of 51% of patients who menstruate reported menstrual disturbance with COVID-19 infection and 21% with COVID-19 vaccination. Symptoms possibly attributable to perimenopause and menopause were highly prevalent among female patients attending post-COVID syndrome clinics in Greater Manchester, England. Our findings provide key prevalence estimates and significant predictors of MSQ scores that are vital for future research, clinical practice, and policy.

Semantics

Original Article